Bristol-Myers Squibb’s Opdivo misses its shot at earlier use in liver cancer

Bristol-Myers Squibb’s Opdivo already boasts an FDA approval in liver cancer patients who have been treated with Nexavar. But its hope to join the Bayer drug in the front line just hit a snag.